EMEA-001971-PIP02-16-M03

Table of contents

Key facts

Invented name
Vitrakvi
Active substance
Larotrectinib
Therapeutic area
Oncology
Decision number
P/0076/2021
PIP number
EMEA-001971-PIP02-16-M03
Pharmaceutical form(s)
  • Capsule, hard
  • Oral solution
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
  • Gastric use
  • Oral use
Contact for public enquiries
Bayer AG

Tel. +49 3046815333
E-mail: pediatrics.medical-affairs-europe@bayer.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

Related content

How useful was this page?

Add your rating